RVPH vs IOTR Comparison

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.

iOThree Ltd is a provider of maritime digital technologies, including satellite connectivity and digitalization solutions in Singapore, focused on facilitating the maritime industry towards digital transformation. It offers shipboard infrastructure to customers by designing and installing the necessary satellite connectivity solution, IT equipment, shipboard equipment (such as equipment relating to navigation systems, automatic identification system, etc.), and JARVISS, a digitalization platform on the vessels of customers. The group's operating segments are: Satellite connectivity solution, which generates key revenue, and Digitalization and other solution. Geographically, it generates maximum revenue from Singapore, and rest from Israel, Malaysia, Vietnam, Thailand, and other regions.